News | September 05, 2025
MedTech Expo 2025: ICMR licenses nine technologies to 17 industry partners
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing
The stethoscope features high acoustic sensitivity and active noise cancellation, minimizing ambient interference to improve auscultation clarity, particularly in noisy hospital settings
Subscribe To Our Newsletter & Stay Updated
